Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 3, 271-280, March 2007; doi:10.1634/theoncologist.12-3-271
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cortes, J.
Right arrow Articles by Baselga, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cortes, J.
Right arrow Articles by Baselga, J.

Breast Cancer

Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Epothilones

Javier Cortes, Jose Baselga

Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Key Words. Epothilones • Review • Breast cancer

Correspondence: Javier Cortes, M.D., Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. Telephone: 0034-948-296696; Fax: 0034-948-255500; e-mail: jacortes{at}vhebron.net

Microtubule-targeting agents such as the taxanes are highly active against breast cancer and have become a cornerstone in the treatment of patients with early and advanced breast cancer. The natural epothilones and their analogs are a novel class of microtubule-stabilizing agents that bind tubulin and result in apoptotic cell death. Among this family of compounds, patupilone, ixabepilone, BMS-310705, ZK-EPO, and KOS-862 are in clinical development. Extensive preclinical studies have shown that epothilones are working through partially nonoverlapping mechanisms of action with taxanes. In the clinic, epothilones have been found in a series of phase I and phase II studies to be active even in patients who had recently progressed to taxanes. The toxicity profile of these agents consists mostly of sensory neuropathy, sometimes reversible. Neoadjuvant studies with epothilones have been conducted and a number of phase III studies in advanced breast cancer are either under way or have been recently completed. The results of these studies are eagerly awaited and it is anticipated that epothilones may become an important treatment option in patients with breast cancer.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
L. B. Michaud
The Epothilones: How Pharmacology Relates to Clinical Utility
Ann. Pharmacother., July 1, 2009; 43(7): 1294 - 1309.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
L. Boehnke Michaud
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer
Journal of Oncology Pharmacy Practice, June 1, 2009; 15(2): 95 - 106.
[Abstract] [PDF]

Home page
 Mayo Clin Proc.Home page
A. Moreno-Aspitia and E. A. Perez
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Mayo Clin. Proc., June 1, 2009; 84(6): 533 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Goodin
Ixabepilone: A novel microtubule-stabilizing agent for the treatment of metastatic breast cancer
Am. J. Health Syst. Pharm., November 1, 2008; 65(21): 2017 - 2026.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. Bhushan and C. M Walko
Ixabepilone: A New Antimitotic for the Treatment of Metastatic Breast Cancer
Ann. Pharmacother., September 1, 2008; 42(9): 1252 - 1261.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. A. Waddell
Introduction
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S2 - S3.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
L. B. Michaud
Treatment-experienced breast cancer
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S4 - S9.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Goodin
Novel cytotoxic agents: Epothilones
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S10 - S15.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
D. G I Kingston
Tubulin-Interactive Natural Products as Anticancer Agents
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 305 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Teicher
Newer Cytotoxic Agents: Attacking Cancer Broadly
Clin. Cancer Res., March 15, 2008; 14(6): 1610 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. J. Lee and S. M. Swain
The Epothilones: Translating from the Laboratory to the Clinic
Clin. Cancer Res., March 15, 2008; 14(6): 1618 - 1624.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement